Abstract 4737
Background
Malignant ependymomas are one of the main types of glioma that have high morbidity and mortality. The objective of this study was to construct, validate and calibrate novel nomograms for the survival of ME patients.
Methods
We utilized the Surveillance, Epidemiology, and End Results database (SEER) to retrieve patients with ME. We excluded patients with an unknown diagnosis, no follow up or with autopsy report only. Moreover, we utilized penalized regression models (PRM) by using “hdnom” package in R with the highest AUC and the most stable calibrations to build nomograms for overall (OS) and cancer-specific survival (CSS).
Results
Data of 3435 patients were retrieved and analyzed. We developed 18 PRM and chose Snet and SCAD for OS and CSS. These two models selected age, sex, year of diagnosis, marital status, site, race, type, surgery, radiation, and chemotherapy for the nomograms to be built. Our nomograms had stable calibrations with adequate to good accuracy AUC of 0.70 to 0.76 for the OS nomogram and AUC of 0.75 to 0.78 for the CSS nomogram.
Conclusions
In this population-based study, we developed nomograms that can better help physicians predict the prognosis and survival of ME patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sherief Ghozy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract